SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-120785
Filing Date
2023-11-22
Accepted
2023-11-22 16:31:12
Documents
6
Period of Report
2023-12-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2329666-1_def14a.htm DEF 14A 984886
2 GRAPHIC bc_cumulative-4clr.jpg GRAPHIC 40511
3 GRAPHIC bc_netincome-4clr.jpg GRAPHIC 42335
4 GRAPHIC lg_nrx-4c.jpg GRAPHIC 19292
5 GRAPHIC px_23nrxannualmeetpg01-bw.jpg GRAPHIC 402684
6 GRAPHIC px_23nrxannualmeetpg02-bw.jpg GRAPHIC 205701
  Complete submission text file 0001104659-23-120785.txt   1928092
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38302 | Film No.: 231433925
SIC: 2834 Pharmaceutical Preparations